The STRONG-HF (Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) trial further reinforced this concept, showing that rapid and intensive GDMT optimization following HF hospitalization led to improved symptoms, quality of life, and reduced 180-day mortality or HF readmission compared with usual care, without major safety concerns [1]. Here, NPPB is linked to heart failure.